Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Moderate to Severe Palmoplantar Psoriasis (GESTURE)
NCT01806597Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of secukinumab in palmoplantar psoriasis, sponsored by Novartis. Started Jun 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
palmoplantar psoriasis
Beyond the preview
Go deeper on NCT01806597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806597.